Remick S C, Neville A J, Willson J K
Cancer Treat Rep. 1987 Jun;71(6):575-80.
A total of 27 untreated and 24 previously treated patients with extensive-disease small cell lung cancer (SCLC) were treated with a combination chemotherapeutic regimen of continuous-infusion etoposide for 5 days, cisplatin, and hexamethylmelamine. of 25 evaluable patients with untreated SCLC, three (12%) achieved a complete response and 16 (64%) achieved a partial response. Among 23 evaluable patients with relapsed SCLC there were no complete responses and nine (39%) achieved a partial response. Median survival times were 252 and 109 days for the above groups, respectively. Myelotoxicity, especially thrombocytopenia, was moderately severe. Other toxic effects, including renal and neurologic, were minimal. These results compare favorably with other regimens including etoposide and cisplatin. Our results further confirm the activity of etoposide and cisplatin as both initial therapy and as a salvage regimen in the management of patients with extensive-stage SCLC.
共有27例未经治疗和24例先前接受过治疗的广泛期小细胞肺癌（SCLC）患者接受了依托泊苷持续静脉输注5天、顺铂和六甲蜜胺联合化疗方案的治疗。在25例可评估的未经治疗的SCLC患者中，3例（12%）达到完全缓解，16例（64%）达到部分缓解。在23例可评估的复发SCLC患者中，无完全缓解，9例（39%）达到部分缓解。上述两组的中位生存时间分别为252天和109天。骨髓毒性，尤其是血小板减少症，为中度严重。包括肾脏和神经毒性在内的其他毒性作用极小。这些结果与包括依托泊苷和顺铂在内的其他方案相比具有优势。我们的结果进一步证实了依托泊苷和顺铂作为广泛期SCLC患者初始治疗和挽救方案的有效性。
